BRAF and neoplasm: Recent research found that the inhibitor of B-Raf (a member of Raf family of serine/threonine protein kinases) exhibited increased tumor immune infiltration (36), and the combination of ICB and B-Raf inhibitor showed improved antitumor activity in BRAF V600E-mutant melanoma (37–39).